Identificatie van hoogrisicastadium I NSCLC met tumorgeïnformeerd plasma-ctDNA

Circulating tumor DNA (ctDNA) has emerged as an important prognostic factor in cancer patients. Management of early stage non-small cell lung cancer (NSCLC) remains challenging with a high rate of disease recurrence. In this prospective cohort, 153 patients with clinical stage I NSCLC (75.8% pathologic stage I) underwent real-time plasma ctDNA testing using a tumor-informed whole exome sequencing approach, RaDaR™. Pre-operative ctDNA was detected in 22.4% of patients (6 weeks median turnaround time) and was significantly associated with recurrence free survival (RFS, HR 3.81, p=0.006).